FDA Center for Drug Evaluation & Research Issues Warning Letter to Hanlim Pharm
October 14, 2026
October 14, 2026
WASHINGTON, Oct. 14 -- The U.S. Department of Health and Human Services Food and Drug Administration issued the following warning letter to Hanlim Pharm Co. Ltd. from its Center for Drug Evaluation and Research:
* * *
Recipient: Mr. Jungjin Kim, Chairman, Hanlim Pharm Co., Ltd., Seocho-Daero, 52-Gil 42 Seongdong-gu, Seoul, South Korea
(b)(4)
Issuing Office: Center for Drug Evaluation and Research (CDER), United States
WARNING LETTE . . .
* * *
Recipient: Mr. Jungjin Kim, Chairman, Hanlim Pharm Co., Ltd., Seocho-Daero, 52-Gil 42 Seongdong-gu, Seoul, South Korea
(b)(4)
Issuing Office: Center for Drug Evaluation and Research (CDER), United States
WARNING LETTE . . .